Contract notice
Section I: Contracting
authority
I.1) Name and addresses
Swansea University
Procurement - Finance, Swansea University, Singleton Park
Swansea
SA2 8PP
UK
Telephone: +44 1792295890
E-mail: procurement@swansea.ac.uk
NUTS: UKL18
Internet address(es)
Main address: www.swansea.ac.uk
Address of the buyer profile: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0345
I.2) Joint procurement
The contract is awarded by a central purchasing body
I.3) Communication
The procurement documents are available for unrestricted and full direct access, free of charge at:
https://etenderwales.bravosolution.co.uk/web/login.shtml
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be sent electronically to:
https://etenderwales.bravosolution.co.uk/web/login.shtml
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Education
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Tender for the Operating Lease of Biological Atomic Force Microscopy (bioAFM)
Reference number: SU135(20)
II.1.2) Main CPV code
38510000
II.1.3) Type of contract
Supplies
II.1.4) Short description
The Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6 million GBP project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is aimed at developing new therapeutics for the treatment of ovarian cancer.
A key output of the CEAT project is to establish a developmental pipeline for bioAFM applications in clinically acceptable in vitro and ex-vivo disease models, providing molecular, cellular and tissue level morphological, topographical and biomechanical information to support epigenomic investigations and the development of advanced therapeutics. As part of this requirement we have identified the need to loan specific bioAFM advanced technology from a reputable, commercial supplier, providing hybrid instrumentation compatible with current bioAFM facilities within SUMS
II.1.5) Estimated total value
Value excluding VAT:
300 000.00
GBP
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.2) Additional CPV code(s)
66114000
II.2.3) Place of performance
NUTS code:
UKL18
Main site or place of performance:
Swansea University Medical School - Singleton Campus
II.2.4) Description of the procurement
he Cluster for Epigenomics and Antibody drug conjugate (ADC) Therapeutics (CEAT) is a 2.6million GBP project, led by the Reproductive Biology and Gynaecological Oncology (RBGO) group at Swansea University Medical School and is aimed at developing new therapeutics for the treatment of ovarian cancer.
A key output of the CEAT project is to establish a developmental pipeline for bioAFM applications in clinically acceptable in vitro and ex-vivo disease models, providing molecular, cellular and tissue level morphological, topographical and biomechanical information to support epigenomic investigations and the development of advanced therapeutics. As part of this requirement we have identified the need to loan specific bioAFM advanced technology from a reputable, commercial supplier, providing hybrid instrumentation compatible with current bioAFM facilities within SUMS
II.2.5) Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6) Estimated value
Value excluding VAT:
300 000.00
GBP
II.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Start:
01/04/2020
End:
31/10/2021
This contract is subject to renewal: No
II.2.9) Information about the limits on the number of candidates to be invited
II.2.10) Information about variants
Variants will be accepted:
No
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
Yes
Section III: Legal, economic, financial and technical information
III.1) Conditions for participation
III.1.2) Economic and financial standing
Selection criteria as stated in the procurement documents
III.2) Conditions related to the contract
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Open procedure
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
IV.2) Administrative information
IV.2.2) Time limit for receipt of tenders or requests to participate
Date:
13/03/2020
Local time: 12:00
IV.2.4) Languages in which tenders or requests to participate may be submitted
EN
CY
IV.2.6) Minimum time frame during which the tenderer must maintain the tender
Duration in months: 3 (from the date stated for receipt of tender)
IV.2.7) Conditions for opening of tenders
Date:
13/03/2020
Local time: 12:00
Place:
Swansea University Procurement
Information about authorised persons and opening procedure:
Category Manager - etenderwales BravoSolution
Section VI: Complementary information
VI.1) Information about recurrence
This is a recurrent procurement:
No
VI.2) Information about electronic workflows
Electronic ordering will be used
Electronic invoicing will be accepted
Electronic payment will be used
VI.3) Additional information
The funding for this equipment is on the basis of an Operating Lease for the duration of the project
NOTE: The authority is using eTenderwales to carry out this procurement process. To obtain further information record your interest on Sell2Wales at https://www.sell2wales.gov.wales/search/search_switch.aspx?ID=99824
(WA Ref:99824)
The buyer considers that this contract is suitable for consortia.
VI.4) Procedures for review
VI.4.1) Review body
High Court
Royal Courts of Justice, The Strand
London
WC2A 2LL
UK
Telephone: +44 2079477501
VI.5) Date of dispatch of this notice
11/02/2020